NEW: No-Cost StreetSmart Live! Events. This type of intellectual capital is usually not made available to the general public. Learn More

Owens & Minor Shares Climb 50% after Raising FY/20 Earnings Guidance by 66%

  ()
Shares of Owens & Minor Inc. reached a new 52-week high after the company raised FY/20 earnings guidance by 66% and advised it expects the positive earnings trend to continue in 2021. read more >

California-Based Biotech Receives COVID-19 Trial Clearance

Research Report
  ()
The timeline and next steps for Equillium's proposed Phase 3 clinical study are outlined in an H.C. Wainwright & Co. report. read more >
News Update

Biotech to Develop Alzheimer's Disease Vaccine Using Proprietary Peptide Antigens

News Update
  ()
ProMIS Neurosciences has demonstrated positive outcomes in proof-of-concept studies. read more >
News Update

Pharmaceutical Firm Reaches 50% Enrollment Mark in Phase 2b/3 Ifenprodil COVID-19 Study

News Update
  ()
Algernon Pharmaceuticals reported it has enrolled the first 75 of 150 patients in a multinational Phase 2b/3 human study of Ifenprodil in treating SARS-CoV-2. read more >

AIM ImmunoTech Achieves 200% Increase in Survival Results in Late-Stage Pancreatic Cancer Study

  ()
AIM ImmunoTech shares traded 20% higher after the firm reported it attained statistically significant, two-fold higher survival results in pancreatic cancer from research conducted at Erasmus University Medical Center in the Netherlands. read more >
News Update

Biopharma Advances Development of Psilocybin-Based Therapeutics

News Update
  ()
Revive Therapeutics provides an update on its psychedelics therapeutics programs. read more >

FDA Grants Ampio Pharma IND and Approves Phase 1 Trial for Inhaled Ampion in COVID-19 Patients

  ()
Ampio Pharmaceuticals traded 15% higher reaching a new 52-week high after the company reported that the U.S. FDA granted an IND and approved the clinical trial protocol for inhaled Ampion for use in COVID-19 patients with respiratory distress. read more >
News Update

Pharma Greenlighted to Continue Multinational COVID-19 Study

News Update
  ()
This confirms the safety of NP-120, the drug Algernon Pharmaceuticals is evaluating in this human trial. read more >
News Update

Expanded Access Protocol for Compassionate Use Approved for Patients with Severe COVID-19

News Update
  ()
Through this program of Revive Therapeutics, qualifying patients will receive Bucillamine, and the biopharma will obtain safety and efficacy data. read more >

Sorrento Receives FDA Clearance to Proceed with Phase 1 COVID-19 Neutralizing Antibody Trial

  ()
Sorrento Therapeutics shares traded more than 10% higher after the company reported it received FDA approval to proceed with its Phase 1 clinical trial of STI-1499 (COVI-GUARD) Neutralizing Antibody in hospitalized COVID-19 patients. read more >

Expert Investing Ideas

"SPR is the number one cannabis stock to own today."

–Cynthia Berryman, Financial News Now


"We expect PMN to forge a licensing deal in Q2/19 or Q3/19."

–André Uddin, Mackie Research Capital


Learn More about Streetwise Reports Live

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Arrowhead Shares Point Higher on Positive Interim Data in Phase 2 Liver Disease Trial

  ()
Shares of Arrowhead Pharmaceuticals traded 48% higher after the firm reported positive interim results from its Phase 2 study of ARO-AAT in patients with alpha-1 antitrypsin deficiency liver disease. read more >

Further Trial Data Analyses 'Reinforce' Profile of Biopharma's Multiple Sclerosis Drug

Research Report
  ()
The confirmatory results concerning Immunic's lead drug candidate IMU-838 are presented in an H.C. Wainwright & Co. report. read more >

Amwell, with $100 Million Google Investment and Access to 80 Million Patients, Expected to Begin Trading on NYSE Sept. 17

Initial Public Offering
  ()
Virtual care company American Well Corp., which operates under the name Amwell®, is expected to begin trading on the New York Stock Exchange on Thursday, September 17, under the symbol AMWL. read more >

Marinus Pharma Shares Sail 50% Higher on Phase 3 Genetic Epilepsy Trial Results

  ()
Marinus Pharmaceuticals shares reached a new 52-week high price after the company reported it achieved the primary endpoint in its Phase 3 Study of ganaxolone for CDKL5 deficiency disorder, a rare type of genetic epilepsy. read more >